

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)			Docket Number: 60068.2US01	Application Number: 10/634,645
			Applicant: ROJAS ET AL.	
			Filing Date: 08/05/2003	Group Art Unit: 1645

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.		DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	6,248,558 B1	06/19/2001	Lin et al.			
	A2	6,254,854 B1	07/03/2001	Edwards et al.			
	A3	6,399,102 B1	06/04/2002	Edwards et al.			
	A4	6,432,680 B1	08/13/2002	Lin et al.			
	A5	6,436,443 B2	08/20/2002	Edwards et al.			
	A6	6,447,752 B2	09/10/2002	Edwards et al.			
	A7	6,447,753 B2	09/10/2002	Edwards et al.			
	A8	6,136,295 C1	10/29/2002	Edwards et al.			
	A9	5,874,064 C1	12/10/2002	Edwards et al.			
	A10	6,503,480 B1	01/07/2003	Edwards et al.			
	A11	2003/0087380 A1	05/08/2003	Fong et al.			
	A12	2003/0099649 A1	05/29/2003	Jacobs et al.			
	A13	2003/0099661 A1	05/29/2003	Valdez et al.			
	A14	2003/0100063 A1	05/29/2003	Fong et al.			
	A15	2003/0104622 A1	06/05/2003	Robbins et al.			
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES NO	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A16	"Alkermes™ Science that Delivers," http://www.alkermes.com/technologies/air_powder.html , 2 pages (printed June 27, 2003).					
	A17	Antonicelli, F. et al., "Nacystelyn Inhibits Oxidant-Mediated Interleukin-8 Expression and NF-κB Nuclear Binding in Alveolar Epithelial Cells," <i>Free Radical Biology & Medicine</i> , Vol. 32, No. 6, pp. 492-502 (2002).					
	A18	Aronica, M.A. et al., "Preferential Role for NF-κB/Rel Signaling in the Type 1 But Not Type 2 T Cell-Dependent Immune Response In Vivo ¹ ," <i>The Journal of Immunology</i> , Vol. 163, pp. 5116-5124 (1999).					
	A19	Baldwin, A.S. Jr., "The NF-κB and IκB Proteins: New Discoveries and Insights," <i>Annu. Rev. Immunol.</i> , Vol. 14, pp. 649-683 (1996).					

EXAMINER <i>RPSwartz</i>	DATE CONSIDERED <i>2-7-05</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	


INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION <small>(Use several sheets if necessary)</small>		Docket Number: 60068.2US01	Application Number: 10/634,645
		Applicant: ROJAS ET AL.	
		Filing Date: 08/05/2003	Group Art Unit: 1645

REC'D - 11/25/2003
JCSP

BPL	A20	Ballard, D.W. et al., "The v-rel Oncogene Encodes a κB Enhancer Binding Protein That Inhibits NF-κB Function," <i>Cell</i> , Vol. 63, pp. 803-814 (November 16, 1990).
	A21	Blackwell, T.S. et al., "Multiorgan Nuclear Factor Kappa B Activation in a Transgenic Mouse Model of Systemic Inflammation," <i>Am. J. Respir. Crit. Care Med.</i> , Vol. 162, No. 3, pp. 1095-1101 (September 2000) (http://ajrccm.atsjournals.org , 18 pages (printed August 15, 2003)).
	A22	Duckett, C.S., "Structure and Function of the NF-kappa-B Family of Transcription Factors," <i>Promega Notes Magazine</i> , No. 44, 6 pages (November 1993).
	A23	Epinat, J.C. et al., "Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway," <i>Oncogene</i> , Vol. 18, No. 49, pp. 6896-6909 (November 22, 1999) (http://www.nature.com , 28 pages (printed August 13, 2003)).
	A24	Ghosh, S. et al., "NF-κB and Rel Proteins: Evolutionarily Conserved Mediators of Immune Responses," <i>Annu. Rev. Immunol.</i> , Vol. 16, pp. 225-260 (1998).
	A25	Jo, D. et al., "Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase," <i>Nature Biotechnology</i> , Vol. 19, No. 10, pp. 929-933 (October 2001) (http://www.nature.com , 11 pages (printed August 13, 2003)).
	A26	Kaiser, J., "Seeking the Cause of Induced Leukemias in X-SCID Trial," <i>Science</i> , Vol. 299, p. 495 (January 24, 2003).
	A27	Lentsch, A.B. et al., "Understanding the Pathogenesis of Inflammation Using Rodent Models," <i>ILAR Journal</i> , Vol. 40, No. 4 (1999) (http://dels.nas.edu , 7 pages (printed June 2, 2003)).
	A28	Li, Q. et al., "NF-κB Regulation in the Immune System," <i>Nature Reviews Immunology</i> , Vol. 2, No. 10, pp. 725-734 (October 2002) (http://www.nature.com , 18 pages (printed August 14, 2003)).
	A29	Lin, Y.Z. et al., "Inhibition of Nuclear Translocation of Transcription Factor NF-κB by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence (*)," <i>JBC Online</i> , Vol. 270, No. 24, pp. 14255-14258 (June 16, 1995) (http://www.jbc.org/cgi/content/full/270/24/14255 , 31 pages (printed August 14, 2003)).
	A30	Lin, Y.Z. et al., "Role of the Nuclear Localization Sequence in Fibroblast Growth Factor-1-stimulated Mitogenic Pathways (*)," <i>JBC Online</i> , Vol 271, No. 10, pp. 5305-5308 (March 8, 1996) (http://www.jbc.org/cgi/content/full/271/10/5305 , 11 pages (printed August 14, 2003)).
	A31	Liu, X.Y. et al., "Identification of a functionally important sequence in the cytoplasmic tail of integrin β ₃ by using cell-permeable peptide analogs," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 11819-11824 (October 1996).
	A32	Marshall, E., "Gene Therapy a Suspect in Leukemia-Like Disease," <i>Science</i> , Vol. 298, pp. 34-35 (October 4, 2002).
	A33	Marshall, E., "Second Child in French Trial is Found to Have Leukemia," <i>Science</i> , Vol. 299, p. 320 (January 17, 2003).
	A34	Marshall, E., "What to Do When Clear Success Comes With an Unclear Risk?," <i>Science</i> , Vol. 298, pp. 510-511 (October 18, 2002).
	A35	Mora, A.L. et al., "Inefficient ZAP-70 Phosphorylation and Decreased Thymic Selection In Vivo Result from Inhibition of NF-κB/Rel ¹ ," <i>The Journal of Immunology</i> , Vol. 167, pp. 5628-5635 (2001) (http://www.jimmunol.org , 18 pages (printed August 14, 2003)).
	A36	McLean, S.J. et al., "Sensitive quantitation of chromium-DNA adducts by inductively coupled plasma mass

EXAMINER: <i>R.P. Swart</i>	DATE CONSIDERED: <i>Z-7-05</i>
-----------------------------	--------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.



INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION <small>(Use several sheets if necessary)</small>		Docket Number: 60068.2US01	Application Number: 10/634,645
		Applicant: ROJAS ET AL.	
		Filing Date: 08/05/2003	Group Art Unit: 1645

		spectrometry with a direct injection high-efficiency nebulizer," <i>Toxicol. Sci.</i> , Vol. 46, No. 2, pp. 260-5 (December 1998) (http://www.ncbi.nlm.nih.gov , 1 page (printed July 1, 2003)).
	A37	Murphy, K.M. et al., "Induction by Antigen of Intrathymic Apoptosis of CD4 ⁺ CD8 ⁺ TCR ^{lo} Thymocytes in Vivo," <i>Science</i> , Vol. 250, p. 1720-1723 (December 21, 1990).
	A38	"Nuclear Factor kappa B-p50/p50 homodimer," http://www.arches.uga.edu/~osuchm/bcmb8010/ , 2 pages (printed June 2, 2003).
	A39	Pahl, H., "Activators and target genes of Rel/NF-κB transcription factors," <i>Oncogene</i> , Vol. 18, No. 49, pp. 6853-6866 (November 22, 1999) (http://www.nature.com , 28 pages (printed August 14, 2003)).
	A40	Rojas, M. et al., "An Alternative to Phosphotyrosine-Containing Motifs for Binding to an SH2 Domain," <i>Biochemical and Biophysical Research Communications</i> , Vol. 234, No. 3, Article No. RC976694, pp. 675-680 (1997).
	A41	Rojas, M. et al., "Controlling Epidermal Growth Factor (EGF)-stimulated Ras Activation in Intact Cells by a Cell-permeable Peptide Mimicking Phosphorylated EGF Receptor," <i>JBC Online</i> , Vol. 271, No. 44, pp. 27456-27461 (November 1, 1996) (http://www.jbc.org/cgi/ , 13 pages (printed August 14, 2003)).
	A42	Seetharaman, R. et al., "Essential Role of T Cell NF-κB Activation in Collagen-Induced Arthritis ¹ ," <i>The Journal of Immunology</i> , Vol. 163, pp. 1577-1583 (1999).
	A43	Tam, J.P. et al., "Peptide synthesis using unprotected peptides through orthogonal coupling methods," <i>Proc. Natl. Acad. Sci USA</i> , Vol. 92, pp. 12485-12489 (December 1995).
	A44	Terpe, K., "Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems," <i>Appl Microbiol Biotechnol</i> , Vol. 60, pp. 523-533 (2003).
	A45	Torchinsky, A. et al., "NF-κB DNA-binding activity in embryos responding to a teratogen, cyclophosphamide," <i>BMC Developmental Biology</i> , Vol. 2, No. 2, 11 pages (2002).
	A46	Turkson, J. et al., "Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation," <i>J. Biol. Chem.</i> , Vol. 276, Issue 48, pp. 45443-45455 (November 30, 2001) (http://www.jbc.org , 23 pages (printed August 14, 2003)).
	A47	Verma, I.M. et al., "Rel/NF-κB/IκB family: intimate tales of association and dissociation," <i>Genes & Development</i> , Vol. 9, pp. 2723-2735 (1995).
	A48	Wang, S. et al., "A Role for a Melosome Transport Signal in Accessing the MHC Class II Presentation Pathway and in Eliciting CD4 ⁺ T Cell Responses ¹ ," <i>The Journal of Immunology</i> , Vol. 163, pp. 5820-5826 (1999).
	A49	Woronicz, J.D. et al., "IκB Kinase-β: NF-κB Activation and Complex Formation with IκB Kinase-α and NIK," <i>Science</i> , Vol. 278, pp. 866-870 (October 31, 1997).
	A50	Wu, Y. et al., "Calmodulin Kinase II and Arrhythmias in a Mouse Model of Cardiac Hypertrophy," <i>Circulation</i> , Vol. 106, No. 10, p. 1288 (http://circ.ahajournals.org , 14 pages, (published online before print August 19, 2002) (printed August 15, 2003)).
	A51	Zhao, Y. et al., "Chemical engineering of cell penetrating antibodies," <i>Journal of Immunological Methods</i> , Vol. 254, pp. 137-145 (2001).

23552

PATENT TRADEMARK OFFICE

EXAMINER <i>R P Stuart</i>	DATE CONSIDERED <i>2-7-05</i>
----------------------------	-------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.